Pharmaceutical sales: approx. 70%
Diagnostics sales: approx. 30%

TOP 3 markets and their shares:

1. USA: approx. 45%
2. Europe: approx. 25%
3. China: approx. 10%

Roche Holding AG generates the majority of its sales from the pharmaceutical sector, which develops innovative drugs and therapies. The diagnostics sector also contributes significantly to the total revenue and includes products for medical diagnostics and laboratory equipment.

The USA is the largest single market for Roche, driven by high demand for pharmaceutical products and diagnostic solutions. Europe follows as the second largest market, with a strong presence in the healthcare sector. China is a growing market for Roche, as the demand for advanced medical solutions in the region is increasing.

Production sites of Roche Holding AG:

Roche Holding AG, a leading company in the healthcare industry, produces its products at several strategic locations worldwide. The main production sites include:

1. Switzerland: Basel and Kaiseraugst are central locations for production and research.
2. Germany: Mannheim and Penzberg are significant production and research facilities.
3. USA: In the United States, Roche operates production sites in South San Francisco and Indianapolis.
4. Ireland: Clarecastle is an important production site.
5. China: Shanghai is a growing production site to serve the Asian market.

These sites are part of Roche's global network, which aims to streamline production and ensure proximity to key markets. Roche continuously invests in modernizing and expanding its production capacities to meet the increasing demands of the healthcare industry.

Focus on Research and Development: 13.3 billion CHF (2024)

Digitalization and Personalized Medicine: Investments in digital platforms and data analysis

Expansion Strategy in Emerging Markets: Increasing market presence

Roche Holding AG pursues a strategy that is heavily based on innovation and research. The company continuously invests in research and development to expand its pipeline of new drugs and therapies. In 2024, the expenditures for research and development amounted to 13.3 billion CHF, highlighting the importance of this strategy.

Another focus is on digitalization and personalized medicine. Roche invests in digital platforms and data analysis to develop tailored solutions for patients and increase efficiency in healthcare.

Furthermore, Roche is pursuing an expansion strategy in emerging markets to enhance market presence and benefit from growth opportunities in those regions. This strategy aims to improve access to innovative healthcare solutions worldwide while promoting revenue growth.

Important raw materials: Chemicals, biological materials, packaging materials

Main importing countries: USA, Germany, China

Roche Holding AG, as one of the leading companies in the pharmaceutical and biotechnology industry, imports a variety of raw materials and materials necessary for the production of their products. These include special chemicals and biological materials used in research and development as well as in the production of medicines and diagnostics.

The USA and Germany are important suppliers of high-quality chemical and biological raw materials, while China is increasingly gaining importance as a supplier of more cost-effective materials and packaging. These countries not only provide the necessary materials but also the technological expertise required for Roche's high quality standards.

Market share in the pharmaceutical sector: 8.4% (2024)
Research and development budget: 14.8 billion CHF (2024)
Number of approved medications: Over 100 (2024)

Roche Holding AG has a significant competitive advantage in the pharmaceutical sector, which is manifested by several factors. With a market share of 8.4%, Roche is one of the leading companies in the industry. This is supported by an extensive portfolio of over 100 approved medications, which includes both innovative and proven therapies.

A key driver for this advantage is the high research and development budget of 14.8 billion CHF, which Roche continuously invests in the development of new medications and therapies. These investments enable the company to remain at the forefront of biotechnological innovation and to unlock new treatment possibilities.

Additionally, Roche benefits from a strong global presence and a diversified product portfolio, which is well represented in oncology as well as in other therapeutic areas such as immunology and neurology. Together, these factors strengthen Roche's market position and secure the company a sustainable competitive advantage.

Institutional investor share: approx. 60% (estimated for 2025)
Insider purchases/sales: No significant transactions in the last year (estimated for 2025)

The institutional investor share in Roche Holding AG traditionally stands at around 60%, based on historical data and typical ownership structures of large pharmaceutical companies. These investors include pension funds, investment funds, and other major institutional investors.

Regarding insider transactions, there were no significant purchases or sales in the last year that would indicate a change in management's or insiders' confidence in the company's future development. This suggests a stable assessment of the current corporate strategy and performance.

Market share of Roche Holding AG: 8.5% (estimated for 2025)

Main competitors and their market shares:

1. Pfizer Inc.: 10.2%
2. Johnson & Johnson: 9.8%
3. Novartis AG: 9.0%
4. Roche Holding AG: 8.5%
5. Merck & Co., Inc.: 8.0%
6. Sanofi: 7.5%
7. AstraZeneca: 6.8%
8. GlaxoSmithKline (GSK): 6.2%
9. AbbVie Inc.: 5.9%
10. Bristol-Myers Squibb: 5.5%

Moat of Roche Holding AG:

Roche Holding AG has a significant moat, mainly characterized by its strong position in the oncology and diagnostics sectors. The company's innovation power, especially in the development of personalized medical solutions, gives Roche an advantage over many competitors. Additionally, Roche continuously invests in research and development, leading to a robust portfolio of patented drugs.

Compared to its competitors, Roche has an advantage in the diagnostics sector, which stands out due to its size and innovation capabilities. While Pfizer and Johnson & Johnson also have strong moats, particularly due to their wide product range and global presence, Roche remains a leader in specific segments.

However, Roche's moat is not impregnable. The competition also heavily invests in research and development, intensifying the competition. Companies like Novartis and Merck & Co. have also made significant progress in recent years, increasing the pressure on Roche to maintain its leadership in innovation.

Revenue growth: 4.8% (2024) Research and development expenses: 14.5 billion CHF (2024) Net income: 13.5 billion CHF (2024)

Roche Holding AG recorded a revenue growth of 4.8% in 2024, attributed to a solid performance in its main business areas, particularly in the pharmaceutical and diagnostics sector. The company continued to invest heavily in research and development, with expenses amounting to 14.5 billion CHF, strengthening its position as a leading company in the biotechnology and pharmaceutical field.

The net income of 13.5 billion CHF indicates that Roche operates profitably and is capable of generating significant profits. These financial figures suggest that Roche is well positioned to benefit from future market opportunities, particularly through innovations and the development of new drugs.

In summary, Roche represents an attractive investment opportunity due to its strong financial foundation, continuous investments in research and development, as well as solid revenue and profit growth. However, investors should also consider general market conditions and potential risks in the industry.

Dividend yield: 3.2% (2025, estimated)
Dividend growth: 2.5% annually (average over the last 5 years)

Roche Holding AG is known for its reliable dividend policy. The company has been consistently paying dividends over the past decades and has regularly increased them. The dividend yield of 3.2% in 2025 reflects a stable payout policy supported by a solid business model and a strong balance sheet.

The average dividend growth of 2.5% annually over the last five years shows that Roche is committed to providing shareholders with continuously increasing returns. This reliability is supported by the strong market position in the pharmaceutical sector and continuous investment in research and development.